ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,560.57
      -0.07%
      US Tech 100
      19,273.20
      -0.16%
      Dow Jones
      40,393.36
      -0.05%
      Brent Oil
      80.63
      -1.09%
      Bitcoin
      65,608.32
      -2.97%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. Europe
      5. EU
      6. Ipsen SA (IPN)

      7. Ipsen SA (IPN) News

      IPN

      Ipsen (IPN)

      Ipsen SA
      		Date:
      Sort by:
       Showing the most relevant articles for your search:EU:IPN
      DateTimeSourceHeadlineSymbolCompany
      07/11/20241:00AMGlobeNewswire Inc.Ipsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potentialEU:IPNIpsen SA
      07/08/202412:00PMGlobeNewswire Inc.Bilan semestriel du contrat de liquidité d'IPSEN - 2024 06 30EU:IPNIpsen SA
      07/08/202412:00PMGlobeNewswire Inc.Half-year statement of IPSEN liquidity agreement - 2024 06 30EU:IPNIpsen SA
      07/02/202412:00PMGlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 26 - 2024EU:IPNIpsen SA
      07/02/202412:00PMGlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024EU:IPNIpsen SA
      07/02/20241:00AMGlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
      07/02/20241:00AMGlobeNewswire Inc.Ipsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trialEU:IPNIpsen SA
      07/02/20241:00AMGlobeNewswire Inc.Ipsen étend sa collaboration et son accord de licence pour le développement de Cabometyx® dans le traitement des tumeurs neuroendocrines avancées sur la base des résultats positifs de l’essai de Phase III CABINETEU:IPNIpsen SA
      06/25/202412:00PMGlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024EU:IPNIpsen SA
      06/25/202412:00PMGlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2024EU:IPNIpsen SA
      06/18/202412:00PMGlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024EU:IPNIpsen SA
      06/18/202412:00PMGlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2024EU:IPNIpsen SA
      06/11/202412:00PMGlobeNewswire Inc.IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 23 - 2024EU:IPNIpsen SA
      06/11/202412:00PMGlobeNewswire Inc.IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024EU:IPNIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitisEU:IPNIpsen SA
      06/10/20244:54PMGlobeNewswire Inc.Le médicament Iqirvo® d’Ipsen obtient l’approbation de la FDA via une procédure accélérée comme traitement PPAR premier de sa classe thérapeutique pour la cholangite biliaire primitiveEU:IPNIpsen SA
      06/07/20241:00AMGlobeNewswire Inc.Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platformEU:IPNIpsen SA
      06/07/20241:00AMGlobeNewswire Inc.Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platformEU:IPNIpsen SA
      06/07/20241:00AMGlobeNewswire Inc.Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de MarengoEU:IPNIpsen SA
      06/06/202412:00PMGlobeNewswire Inc.Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital socialEU:IPNIpsen SA
      06/06/202412:00PMGlobeNewswire Inc.Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capitalEU:IPNIpsen SA
      06/06/20248:30AMGlobeNewswire Inc.Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   EU:IPNIpsen SA
      06/06/20248:30AMGlobeNewswire Inc.Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer   EU:IPNIpsen SA
      06/06/20248:30AMGlobeNewswire Inc.Ipsen nomme Josep Catllà, en qualité de Vice-Président Exécutif, Chief Corporate Affairs OfficerEU:IPNIpsen SA
      06/05/20242:00AMGlobeNewswire Inc.Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis    EU:IPNIpsen SA
      06/03/20241:00AMGlobeNewswire Inc.Ipsen initiates a share buy-back program to cover its free employee share-allocation planEU:IPNIpsen SA
      06/03/20241:00AMGlobeNewswire Inc.Ipsen lance un programme de rachat d’actions pour couvrir son programme d’attribution d’actions gratuites aux salariésEU:IPNIpsen SA
      05/30/202412:15PMGlobeNewswire Inc.Ipsen annonce le lancement d'une opération d’actionnariat salariéEU:IPNIpsen SA
      05/30/202412:15PMGlobeNewswire Inc.Ipsen announces the launch of an employee shareholding planEU:IPNIpsen SA
       Showing the most relevant articles for your search:EU:IPN

      Your Recent History

      USOTC
      XPNGF
      Xpeng (PK)
      Delayed Upgrade Clock